266 related articles for article (PubMed ID: 11365016)
21. Antiviral update.
PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
[TBL] [Abstract][Full Text] [Related]
22. Update on antivirals.
PI Perspect; 1996 Sep; (No 19):7-9. PubMed ID: 11363906
[TBL] [Abstract][Full Text] [Related]
23. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
24. Now there are eleven, but so what?
Gilden D
GMHC Treat Issues; 1997; 11(4/5):1-3. PubMed ID: 11364371
[TBL] [Abstract][Full Text] [Related]
25. Protease inhibitors: no knockout blow, but could be the best punch yet.
AIDS Alert; 1996 Apr; 11(4):37-9. PubMed ID: 11363400
[TBL] [Abstract][Full Text] [Related]
26. AIDS researchers emphasize new drug combinations.
Fox JL
Nat Biotechnol; 1997 Mar; 15(3):215. PubMed ID: 9062914
[No Abstract] [Full Text] [Related]
27. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
Vazquez E
Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
[TBL] [Abstract][Full Text] [Related]
28. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
29. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
James JS
AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
[TBL] [Abstract][Full Text] [Related]
30. New drug approved to treat HIV.
Treat Rev; 1997 Apr; (No 24):5. PubMed ID: 11364284
[TBL] [Abstract][Full Text] [Related]
31. Protease inhibitors and nucleoside combinations, or, Alice in Gaithersburg.
Mascolini M
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):23-32, 37. PubMed ID: 11363515
[TBL] [Abstract][Full Text] [Related]
32. State of the art: antiretroviral and prophylactic treatments in HIV/AIDS.
Porche DJ
Nurs Clin North Am; 1999 Mar; 34(1):95-112. PubMed ID: 9922281
[TBL] [Abstract][Full Text] [Related]
33. Another take on when to start and how to succeed.
Friedland GH
AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
[No Abstract] [Full Text] [Related]
34. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
35. Delavirdine dilemma at the FDA. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1996 Dec; 10(12):4-5. PubMed ID: 11364017
[TBL] [Abstract][Full Text] [Related]
36. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
[TBL] [Abstract][Full Text] [Related]
37. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
38. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
39. Antiviral update.
PI Perspect; 1997 Mar; (No 21):8-10. PubMed ID: 11364216
[TBL] [Abstract][Full Text] [Related]
40. Nelfinavir (Viracept).
Baker R; Bowers M
BETA; 1997 Mar; ():5. PubMed ID: 11364528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
